Recent News

In the past 30 years, major strides have been made in translational medicine — the bridge that shepherds research findings from the lab to clinical practice. Researchers, physicians, and other specialists at Memorial Sloan Kettering Cancer Center (MSK) have played a major role in these successes, as they work together with the common goal of using their discoveries to create new treatments for people with cancer.

Unlike most small cell lung cancer tumors, these retain a normal copy of a protein called RB.

The revised scoring system incorporates molecular information related to 31 genes to help predict risk.

Called NEXT, the factor plays an important role in handing over RNA to the exosome for destruction.

The findings could pave the way toward more targeted treatments for the disease.

At Memorial Sloan Kettering Cancer Center’s 43rd annual event recognizing graduates and award winners, honorees were welcomed back to an in-person event.

By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.

Eight scientists are poised to receive their doctorates and embark on careers tackling problems in human disease through biomedical research. Their years of dedication and training will be recognized on May 18, 2022, when they will be awarded their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK). This year’s commencement marks the school’s 11th graduating class since admitting its first students in 2006.

By detecting molecular signatures in the blood, the sensor may help improve cancer screenings.

The new cells, which the scientists have dubbed killer innate-like T cells, differ in several notable ways from the conventional target of many immunotherapies.